Similarly, we did not consider use of renin–angiotensin system inhibitors alone, despite their common use in this population for the management of comorbidities (such as hypertension, diabetes, coronary artery disease and chronic kidney disease), as primary trials did not meet their primary endpoints28,29 and these therapies are not approved for this indication. This evidence concerns the gene REN and Hypertension.